FDA warned pharmahealthonline.com for selling unapproved, misbranded opioid and benzodiazepine drugs to U.S. consumers online.
What happened
FDA reviewed the website www.pharmahealthonline.com and found it offered unapproved and misbranded opioid and benzodiazepine drugs to U.S. consumers. Examples included tramadol marketed as “JPDOL-100,” alprazolam marketed as “Ksalol 1mg,” and clonazepam marketed as “Rivotril 2mg.” FDA found this by reviewing the website, not through an inspection.
What FDA found
The website sells tramadol, alprazolam, and clonazepam that are not approved by FDA.
21 U.S.C. § 355(a); FD&C Act § 505(a)Selling these unapproved new drugs in interstate commerce violates the FD&C Act.
21 U.S.C. § 331(d); FD&C Act § 301(d)The drug labeling lacks adequate directions for a layperson to use them safely.
21 U.S.C. § 352(f)(1); FD&C Act § 502(f)(1)Offering these misbranded drugs for sale causes them to be introduced into interstate commerce.
21 U.S.C. § 331(a); FD&C Act § 301(a)
What FDA wants
FDA asks the company to stop offering any unapproved and misbranded drugs to U.S. consumers and to respond in writing within 15 working days with corrective steps and documentation.
Who should pay attention
- online pharmacies selling to U.S. consumers
- companies sourcing or reselling opioid or benzodiazepine products
- payment and shipping services supporting online drug sales
This is a summary. Read the original letter on fda.gov.